Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203

Weijing Sun*, Mark Powell, Peter J. O'Dwyer, Paul Catalano, Rafat H. Ansari, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

213 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science